%0 Journal Article
%A Perovnik, Matej
%A Simončič, Urban
%A Jamšek, Jan
%A Gregorič Kramberger, Milica
%A Brumberg, Joachim
%A Meyer, Philipp Tobias
%A Perani, Daniela
%A Caminiti, Silvia Paola
%A Brendel, Matthias
%A Stockbauer, Anna
%A Camacho, Valle
%A Alcolea, Daniel
%A Vandenberghe, Rik
%A Van Laere, Koen
%A Ko, Ji Hyun
%A Lee, Chong Sik
%A Pardini, Matteo
%A Lombardo, Lorenzo
%A Padovani, Alessandro
%A Pilotto, Andrea
%A Ochoa-Figueroa, Miguel A
%A Davidsson, Anette
%A Cháfer-Pericás, Consuelo
%A Álvarez-Sánchez, Lourdes
%A Garibotto, Valentina
%A Lemstra, Afina W
%A Ferreira, Daniel
%A Morbelli, Silvia Daniela
%A Tang, Chris C
%A Eidelberg, David
%A Trošt, Maja
%T Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stages.
%J Journal of neurology, neurosurgery, and psychiatry
%V 97
%N 4
%@ 0022-3050
%C London
%I BMJ Publishing Group
%M DZNE-2026-00296
%P 316 - 324
%D 2026
%X Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia, yet it remains under-recognised and misdiagnosed, which delays treatment, causes inaccurate prognosis and limits research opportunities. Imaging with 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) is a supportive DLB biomarker. We evaluated a multivariate, quantifiable metabolic network biomarker, termed DLB-related pattern (DLBRP), for its further clinical translation across centres and disease stages.We analysed demographic, clinical and FDG PET imaging data of 1180 participants from 14 tertiary centres and two multicentre datasets. We included 379 DLB, 28 mild cognitive impairment-LB (MCI-LB), 195 dementia due to Alzheimer's disease (ADD), 172 MCI-AD without α-synuclein co-pathology (MCI-AD-S-), and 73 MCI-AD with α-synuclein co-pathology (S+) patients, along with a comparative group of 333 normal controls (NCs). From the scans, we calculated the expression of DLBRP, AD-related pattern (ADRP) and Parkinson's disease-related pattern (PDRP) and compared them across groups. DLBRP scores were correlated with clinical measurements.Across independent cohorts, DLBRP robustly distinguished DLB from NCs (sensitivity >89
%K Humans
%K Lewy Body Disease: metabolism
%K Lewy Body Disease: diagnostic imaging
%K Male
%K Female
%K Aged
%K Positron-Emission Tomography
%K Cognitive Dysfunction: metabolism
%K Cognitive Dysfunction: diagnostic imaging
%K Brain: metabolism
%K Brain: diagnostic imaging
%K Fluorodeoxyglucose F18
%K Alzheimer Disease: metabolism
%K Alzheimer Disease: diagnostic imaging
%K Aged, 80 and over
%K Disease Progression
%K Biomarkers: metabolism
%K Prodromal Symptoms
%K Middle Aged
%K ALZHEIMER'S DISEASE (Other)
%K LEWY BODY DEMENTIA (Other)
%K PET, FUNCTIONAL IMAGING (Other)
%K Fluorodeoxyglucose F18 (NLM Chemicals)
%K Biomarkers (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41344886
%R 10.1136/jnnp-2025-336935
%U https://pub.dzne.de/record/285739